Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer: A multicenter, prospective, cohort study

Jie Liu; Hong-sheng Lin; Wei Hou; Bao-jin Hua; Pei-tong Zhang; Jie Li; Shen-yu Wang; Ying Xie; Yue Zhang; Guang-ru Xie; Mei-ying Zhang; Wen-guang Shi; Nian-bo Guan; Tian-yu Guan; Cong-huang Li; Li-yuan Lu; Ying Zhang; Dao-rui Li; Hao Liu

doi:10.1007/s11655-016-2737-1

Your Location：

Home >

Browse articles >

Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer: A multicenter, prospective, cohort study

OriginalPaper | Updated：2021-08-27

- Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer: A multicenter, prospective, cohort study
- Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer: A multicenter, prospective, cohort study
- 中国结合医学杂志（英文版） 2017年23卷第10期页码：733-739
- Affiliations：
  
  1. Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences,Beijing,China
  2. Department of Integrative Oncology, Liaoning Cancer Hospital,Shenyang,China
  3. Department of Traditional Chinese Medicine, Shanxi Cancer Hospital,Xi’an,China
  4. Traditional Chinese Medicine Department, Jilin Cancer Hospital,Changchun,China
  5. Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital,Tianjin,China
- Author bio：
- Funds：
  
  Supported by National Key Technologies Research and Development Program for the 11th Five-Year Plan (No. 2006BAI04A05)
- DOI：10.1007/s11655-016-2737-1
  中图分类号：
- 纸质出版日期：2017，
  
  网络出版日期：2016-10-28，
Scan for full text
Liu, J., Lin, Hs., Hou, W. et al. Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer: A multicenter, prospective, cohort study., Chin. J. Integr. Med. 23, 733–739 (2017). https://doi.org/10.1007/s11655-016-2737-1

Jie Liu, Hong-sheng Lin, Wei Hou, et al. Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer: A multicenter, prospective, cohort study[J]. Chinese Journal of Integrative Medicine, 2017,23(10):733-739.
Liu, J., Lin, Hs., Hou, W. et al. Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer: A multicenter, prospective, cohort study., Chin. J. Integr. Med. 23, 733–739 (2017). https://doi.org/10.1007/s11655-016-2737-1 DOI：

Jie Liu, Hong-sheng Lin, Wei Hou, et al. Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer: A multicenter, prospective, cohort study[J]. Chinese Journal of Integrative Medicine, 2017,23(10):733-739. DOI： 10.1007/s11655-016-2737-1.

摘要

To determine whether additional Chinese medicine (CM) could prolong survival and improve the quality of life (QOL) in patients with advanced non-small cell lung cancer (NSCLC) compared with Western medicine (WM) alone. This was a multicenter

prospective cohort study. A total of 474 hospitalized patients with stage III–IV NSCLC were recruited and divided into 2 groups. Patients in the WM group received radiotherapy

chemotherapy

and optimal supportive therapy according to the National Comprehensive Cancer Network (NCCN) guidelines. In the integrative medicine (IM) group

individualized CM (Chinese patent medicines and injections) and WM were administered. The primary end point was overall survival

and the secondary end points were time to disease progression

adverse events

and QOL. Follow-up clinical examinations and chest radiography were performed every 2 months. The median survival was 16.60 months in the IM group and 13.13 months in the WM group (P<0.01). The incidences of loss of appetite

nausea

and vomiting in the IM group were significantly lower than those in the WM group (P<0.05). The QOL based on Functional Assessment of Cancer Therapy-Lung in the IM group was markedly higher than that in the WM group at the fourth course (P<0.05). Additional CM may prolong survival and improve the QOL patients with NSCLC. The adverse effects of radio- and chemotherapy may be attenuated as CM is used in combination with conventional treatments.

Abstract

prospective cohort study. A total of 474 hospitalized patients with stage III–IV NSCLC were recruited and divided into 2 groups. Patients in the WM group received radiotherapy

chemotherapy

and optimal supportive therapy according to the National Comprehensive Cancer Network (NCCN) guidelines. In the integrative medicine (IM) group

individualized CM (Chinese patent medicines and injections) and WM were administered. The primary end point was overall survival

and the secondary end points were time to disease progression

adverse events

nausea

关键词

advanced non-small cell lung cancerChinese MedicineIntegrative Medicine

Keywords

advanced non-small cell lung cancerChinese MedicineIntegrative Medicine

references

GLOBOCAN 2012 (IARC) Section of Cancer Information. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Available at: http:// globocan.iarc.fr/Default.aspx.

Chen WQ, Zheng RS, Baade PD, Zhang SW, Zeng HM, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115–132.

Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER cancer statistics review, 1975–2007. National Cancer Institute; 2010. Available at: http://seer. cancer.gov/csr/previous.html.

Mountain CF. Revisions in the international staging system for staging lung cancer. Chest 1997;111:1710–1717.

National Comprehensive Cancer Network. NCCN clinical practice guideline in oncology: non-small cell Lung cancer vision 2016. Available at: https://www.nccn.org/.

American Joint Committee on Cancer. AJCC Cancer Staging Manual 2002;167-177.

National Comprehensive Cancer Network. NCCN clinical practice guideline in oncology: non-small cell lung cancer vision, Chinese edition. Available at: http://www.nccn.org.

Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumor: immunerelated response criteria. Clin Cancer Res 2009;15:7412–7420.

Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995;12:199–220.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.

Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma—with particular reference to bronchogenic carcinoma. Cancer 1948;1:634–656

National Cancer Institute: Common terminology criteria for adverse events v3.0 (CTCAE). Available at: http://ctep. cancer.gov/protocoldevelopment/electronic_applications/ docs/ctcaev3.

Brookmeyer R, Crowley JJ. A confidence interval for median survival time. Biometrics 1982;38:29–41.

Fisher MD, D'Orazio A. PhaseIIand III trials: comparison of four chemotherapy regimens in advanced non small cell lung cancer (ECOG 1594). Clin Lung Cancer 2000;2:21–22.

Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, et al. European Organization for Research and Treatment of Cancer Lung Cancer Group. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group— EORTC 08975. J Clin Oncol 2003;21:3909–3917.

Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, et al. Italian Lung Cancer Project. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285–4291.

Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210–3218.

Belani CP, Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced non-small cell lung carcinoma (TAX 326). Cancer 2005;104:2766–2774.

Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12:175–180.

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for nonsmall- cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380–2388.

Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735–742.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol 2012;13:239–246.

Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014;370:1189–1197.

Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus pemetrexed–cisplatin orpemetrexed—carboplatin in patients with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). J Clin Oncol 2014;32(5 Suppl):8002.

Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in avanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123–135.

Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabinewith cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543–3551.

National Comprehensive Cancer Network. NCCN clinical practice guideline in oncology: non-small cell lung cancer vision. 2009. Available at: http://www.nccn.org.

Stinchcombe TE, Choi J, Schell MJ, Mears A, Jones PE, Nachtsheim RV, et al. Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status. Lung Cancer 2006;51:237–243.

Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991;9:1618–1626.

Li J, Lin HS. Integrative medicine: a characteristic China model for cancer treatment. Chin J Integr Med 2011;17:243–245.

Liu J, Wang S, Lin HS. Traditional Chinese medicine and cancer: history, present situaiton and development. Thoracic Cancer 2015;6:561–569.

FULL TEXT LINK

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Chinese medicine education and its challenges in the United States

Search of novel model for integrative medicine

The treatment of non-small cell lung cancer by interstitial I-125 seeds implantation combined with chemotherapy and Chinese medicine

Clinical study on treatment of infantile cytomegalovirus hepatitis with integrated Chinese and Western medicine

Which research is needed to support clinical decision-making on integrative medicine?—Can comparative effectiveness research close the gap?